The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials
Open accessAbstract
OBJECTIVES: This study aimed to systematically review the literature on the efficacy and immunogenicity of single-dose HPV vaccination compared to no vaccination or multi-dose schedules among vaccine trial participants. METHODS: Medline, EMBASE, Global Health Database and Cochrane Central Register of Controlled Trials were searched for publications and conference abstracts (dated January 1999-August 2018) using MeSH and non-MeSH terms for human papillomavirus AND vaccines AND (immunogenicity OR efficacy/effectiveness) AND dosage. Search results were screened against pre-specified eligibility criteria. Data were extracted from included articles, and a narrative synthesis conducted on efficacy against HPV16/18 infection and humoral immunogenicity. RESULTS: Seven of 6,523 unique records identified were included in the review. Six were nested observational studies of participants randomised to receive two or three doses in three large HPV vaccine trials, in which some participants did not complete their allocated schedules. One small pilot study prospectively allocated participants to receive one or no vaccine dose. Frequency of HPV16/18 infection was low (e.g. <1% for 12-month-persistent infection) in all vaccinated participants up to seven years post vaccination and did not significantly differ by number of doses (p > 0.05 in all cases). Frequency of infection was significantly lower in one-dose recipients compared to unvaccinated controls (p < 0.01 for all infection endpoints in each study). HPV16/18 seropositivity rates were high in all HPV vaccine recipients (100% in three of four studies reporting this endpoint), though antibody levels were lower with one compared to two or three doses. CONCLUSIONS: This review supports the premise that one HPV vaccine dose may be as effective in preventing HPV infection as multi-dose schedules in healthy young women. However, it also highlights the paucity of available evidence from purpose-designed, prospectively-randomised trials. Results from ongoing clinical trials assessing the efficacy and immunogenicity of single-dose HPV vaccination compared to currently-recommended schedules are awaited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, the IARC India trial with a quadrivalent vaccine, and the Costa Rica Trial with a bivalent vaccine, have shown comparable efficacy between single-dose and multi-dose schedules, with sustained antibody levels for at least 11 years after vaccination.”
From Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which currently provides the best data on single-dose protection because of its long follow-up and near-random assignment of participants to different dose schedules.10, 11”
From Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study (2022) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Global Burden of Human Papillomavirus and Related Diseases
Forman, D., de Martel, C., Lacey, C. J., Soerjomataram, I., Lortet‐Tieulent, J., Bruni, L., Vignat, J., Ferlay, J., Bray, F., Plummer, M., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.07.055 · Cited by 1,685
Paavonen, J., Naud, P., Salmerón, J., Wheeler, C., Chow, S.-N., Apter, D., Kitchener, H., Castellsague, X., Teixeira, J., Skinner, Sr., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61248-4 · Cited by 1,655
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
Joura, E. A., Giuliano, A. R., Iversen, O.-E., Bouchard, C., Mao, C., Mehlsen, J., Moreira, E. D., Ngan, Y., Petersen, L. K., Lazcano-Ponce, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405044 · Cited by 1,433
A review of clinical trials of human papillomavirus prophylactic vaccines
Schiller, J. T., Castellsagué, X., & Garland, S. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.108 · Cited by 747
Simms, K. T., Steinberg, J., Caruana, M., Smith, M. A., Lew, J.-B., Soerjomataram, I., Castle, P. E., Bray, F., & Canfell, K. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30836-2 · Cited by 486
The projected timeframe until cervical cancer elimination in Australia: a modelling study
Hall, M. T., Simms, K. T., Lew, J., Smith, M. A., Brotherton, J. M. L., Saville, M., Frazer, I. H., & Canfell, K. (2018) · The Lancet Public Health · doi:10.1016/s2468-2667(18)30183-x · Cited by 448
Kreimer, A. R., Rodríguez, A. C., Hildesheim, A., Herrero, R., Porras, C., SCHIFFMAN, M. H., González, P., Solomon, D., Jiménez, S., Schiller, J. T., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr319 · Cited by 324
Self-citationKreimer, A. R., Struyf, F., Rosario‐Raymundo, M. R. D., Hildesheim, A., Skinner, S. R., Wacholder, S., Garland, S. M., Herrero, R., David, M., & Wheeler, C. M. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00047-9 · Cited by 316
Self-citationBrisson, M., Bénard, É., Drolet, M., Bogaards, J. A., Baussano, I., Vänskä, S., Jit, M., Boily, M.-C., Smith, M. A., Berkhof, J., et al. (2016) · The Lancet Public Health · doi:10.1016/s2468-2667(16)30001-9 · Cited by 307
Self-citation
Research works printed but not linked: 2
- WHO. Human papillomavirus vaccines: WHO position paper, October 2014. Weekly Epidemiological Record. 2014;89(43):465–92.
- Deeks JJ, Higgins JP. Statistical algorithms in review manager 5. Statistical Methods Group of The Cochrane Collaboration; 2010. p. 1–11.
Cited by
Sorted by citations
Items 101–118 of 118
Impact of a human papillomavirus vaccination clinical program in a commercially insured population
Pelaccio, K., Mo, M., Olmsted, A., & DeJager, K. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.30.12.1405
Pinto-Santini, D., Jalil, E. M., Fernandes, G. T., Hilaire, G., Kolevic, L., Cabello, R. L., Grinsztejn, B. G. J., Pape, W., Deschamps, M., House, M. G., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13551-z
Prevention of human papillomavirus-associated cervical disease in the 21st century
Ansarova, S. M., Basalova, J. V., Heydarova, A. E. K., Grineva, A. A., Obukhova, E. П., Romanenko, M. S., & Raevskii, K. P. (2025) · Russian Medicine · doi:10.17816/medjrf643669
Amarasena, W. D. J. K., Goonewardena, S., & Gamage, D. (2026) · Infectious Agents and Cancer · doi:10.1186/s13027-026-00759-2
Evaluation of Anti-HPV18 Antibody Titers Preceding an Incident Cervical HPV18/45 Infection
Wiek, F., Shankar, V., Gradíssimo, A., Díaz, Á., Pinto, L. A., Schlecht, N. F., & Burk, R. D. (2025) · Vaccines · doi:10.3390/vaccines13070722
Gupta, S., Basu, S., & Banerjee, R. (2024) · The Evidence · doi:10.61505/evidence.2024.2.2.71
Mishra, P., Sharma, R., Srivastava, A., Bhadouria, N., & Mandal, S. (2025) · Journal of South Asian Federation of Obstetrics and Gynaecology · doi:10.5005/jp-journals-10006-2728
Wonodi, C. B., Ahmed, R. G., Etamesor, S., Ezeanya, N., Angioha, P. U., Aliyu, L., Abdulkadir, A. J., Okpe, I., Abdulsalam, L., Shola, O. B., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7715117/v1
Memory B-cells elicited by different HPV vaccine regimens in the DoRIS randomised controlled trial
Wiggins, R. C., Baisley, K. J., Indangasi, J., Changalucha, J. M., Ashwin, H. M., Brown, N., Whitworth, H. S., Joakim, D., Mayaud, P., Hashim, R., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01313-8
Self-citationPrem, K., Choi, Y. H., Bénard, É., Burger, E. A., Hadley, L., Laprise, J.-F., Regan, M. C., Drolet, M., Sy, S., Abbas, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26611787
Self-citationOsmani, V., Fett, S., Tauscher, M., Donnachie, E., Schneider, A., & Klug, S. J. (2023) · Figshare · doi:10.6084/m9.figshare.22616786
Investigation of Nursing Students' Knowledge Levels About Human Papillomavirus
Saydamlı, Ş., Hitay, İ., Er, M. N., & Çolak, H. (2025) · Türk hemşireler derneği dergisi. · doi:10.70479/thdd.1811980
Cost-utility analysis of free HPV immunization for girls in Rajasthan, India
Munot, S., Prasad, N., Paudel, R., Gaurav, S., Saunik, S., Paulino-Ramírez, R., Ottoho, E., Volquez, M., Ripon, R. K., Manghani, P., et al. (2026) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-025-00708-7
Kuhlmey, E., Polavarapu, T., Semprini, J., & Reimer, R. A. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128598
Economic burden of human papillomavirus-related cancers in New Zealand
Koh, S. P., Stephenson, C., Chaplin, J. M., Ruske, D., Macann, A., Denison, H. J., Sykes, P. H., Ji, E., Young, M. R., Jenkinson, A., et al. (2026) · BMJ Public Health · doi:10.1136/bmjph-2025-003800
Economic Evaluation of HPV Vaccination and Cervical Cancer Screening
Lu, K. (2026) · BIO Web of Conferences · doi:10.1051/bioconf/202624001034
Whitworth, H. S., Beshir, K. B., Baisley, K. J., Mbwanji, G., Indangasi, J., Kemp, T. J., Kamala, B., Maxwell, C., Hashim, R., Mukerebe, C., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128889
Self-citationA Mathematical Method for Assessing HPV Transmission and Cervical Cancer Prevention Options
Saradha, M., Deepa, B. G., Lakshmi, D. V., Kavitha, & Nayana, S. N. (2026) · Lecture notes in electrical engineering · doi:10.1007/978-3-032-25038-4_4
Metadata
- Authors
- Whitworth, H. S., Gallagher, K. E., Howard, N., Mounier-Jack, S., Mbwanji, G., Kreimer, A. R., Basu, P., Kelly, H., Drolet, M., Brisson, M., & Watson-Jones, D.
- Affiliations
- London School of Hygiene & Tropical Medicine (GB)
- Mwanza Intervention Trials Unit (TZ)
- National Institutes of Health (US)
- Centre international de recherche sur le cancer (FR)
- Centre de recherche du CHU de Québec-Université Laval (CA)
- Université Laval (CA)
- Corresponding author
- Whitworth, Hilary S.
- ORCID
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 38
- Issue
- 6
- Pages
- 1302-1314
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W2995954663
- Cited by
- 118
- References
- 34
- Citations by year
- 2026: 9 · 2025: 20 · 2024: 25 · 2023: 20 · 2022: 19 · 2021: 17 · 2020: 8
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Vaccine (publishedVersion, cc-by)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- National University of Singapore (submittedVersion)
- Funders
- PATH
- Topics
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Health Sciences › Medicine › Surgery › Genital Health and Disease
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- HPV vaccine, single-dose vaccination, HPV16/18 infection, immunogenicity, vaccine efficacy, dosing regimen, seropositivity, antibody levels, HPV prevention, young women
- MeSH terms
- Immunogenicity, Vaccine, Female, Humans, Immunization Schedule, Vaccination, Randomized Controlled Trials as Topic, Papillomavirus Infections, Human papillomavirus 18, Human papillomavirus 16, Papillomavirus Vaccines, Immunity, Humoral, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
